A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate, Biochemically Relapsed Prostate Cancer
Annual rept. 17 Aug 2013-16 Aug 2014
CORNELL UNIV NEW YORK
Pagination or Media Count:
Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 5 subjects at WCMC. An additional 33 subjects enrolled 28 treated at participating sub-sites. Reports submitted to WCMC DSMB in July 2014 with approval to proceed without modifications.
- Medicine and Medical Research